Abstract

Esophageal squamous cell carcinoma (ESCC), a major histologic type of esophageal cancer, is one of the frequent causes of cancer-related death worldwide. Picropodophyllotoxin (PPT) is the main component of Podophyllum hexandrum root with antitumor activity via apoptosis-mediated mechanisms in several cancer cells. However, the underlying mechanism of the PPT effects in apoptosis induction in cancer remains ambiguous. Hence, in this study, we evaluate the anti-cancer effects of PPT in apoptotic signaling pathway-related mechanisms in ESCC cells. First, to verify the effect of PPT on ESCC cell viability, we employed an MTT assay. PPT inhibited the viability of ESCC cells in time- and dose-dependent manners. PPT induced G2/M phase cell cycle arrest and annexin V-stained cell apoptosis through the activation of the c-Jun N-terminal kinase (JNK)/p38 pathways. Furthermore, the treatment of KYSE 30 and KYSE 450 ESCC cells with PPT induced apoptosis involving the regulation of endoplasmic reticulum stress- and apoptosis-related proteins by reactive oxygen species (ROS) generation, the loss of mitochondrial membrane potential, and multi-caspase activation. In conclusion, our results indicate that the apoptotic effect of PPT on ESCC cells has the potential to become a new anti-cancer drug by increasing ROS levels and inducing the JNK/p38 signaling pathways.

Highlights

  • An estimated 18,440 new cases and 16,170 deaths from esophageal cancer are projected in the United States in 2020 [1,2,3,4,5]

  • We report here that PPT induces apoptosis in Esophageal squamous cell carcinoma (ESCC) cells by reactive oxygen species (ROS) generation, endoplasmic reticulum (ER) stress production, and Jun N-terminal kinase (JNK)/p38 activation

  • The effects of PPT on ESCC cell viability were investigated by an 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay

Read more

Summary

Introduction

An estimated 18,440 new cases and 16,170 deaths from esophageal cancer are projected in the United States in 2020 [1,2,3,4,5]. The cyclolignan PPT, one of the aryl tetralin lignans, was launched as an anticancer drug targeting insulin-like growth factor 1 receptor (IGF-1R) [11]. It induces G2/M phase arrest and apoptosis in multiple myeloma cells by inhibiting IGF-1R [13]. JNK/p38 MAPK signaling pathways activation suppressed tumorigenesis and cancer growth by promoting cell death [18,19,20]. It is not clear whether JNK and p38-MAPK signaling are involved in PPT-induced cancer cell apoptosis. We report here that PPT induces apoptosis in ESCC cells by reactive oxygen species (ROS) generation, endoplasmic reticulum (ER) stress production, and JNK/p38 activation

PPT Inhibits ESCC Cell Proliferation and Anchorage-Independent Growth
PPT Promotes ESCC Cells Apoptosis Through Increasing Multi-Caspase Activity
Chemicals and Reagents
Cell Culture
Cell Viability Assay
Soft Agar Assay
Cell Cycle Analysis
Western Blots
ROS Assay
Mitochondrial Membrane Potential Assay
4.10. Preparation of Cytosolic and Mitochondrial Fractions
4.11. Multi-Caspase Activity
4.12. Statistical Analysis

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.